OncLive SOSS

Authors

Brendon M. Stiles, MD

Latest:

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Panelists discuss how financial toxicity and cost-effectiveness analyses highlight the importance of appropriate patient selection for perioperative immunotherapy, while emphasizing that multidisciplinary care and patient involvement remain essential for optimal outcomes.

Brian A. Moore, MD, FACS

Latest:

Remote Monitoring Enhances Care for Patients With Head and Neck Cancer

If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.

Brian A. Van Tine, MD, PhD

Brian A. Van Tine, MD, PhD, is a professor of medicine in the John T. Milliken Department of Medicine Division of Oncology at the Washington University School of Medicine

Latest:

Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Brian A. Van Tine, MD, PhD, Siteman Cancer Center

Brian Baumann, MD

Latest:

Dr. Brian Baumann on the Impact of Skin Cream Use Prior to Radiation

Brian Baumann, MD, medical oncologist, University of Pennsylvania, discusses the impact of skin creams on radiation.

Brian D. Crompton, MD

Latest:

Dr. Crompton on the Potential for Liquid Biopsies in Pediatric Sarcomas

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the potential of liquid biopsies in the treatment of pediatric patients with sarcoma.

Brian F. Chapin, MD

Latest:

Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Brian G. M. Durie, MD

Latest:

Dr. Durie on a More Sensitive Automated Flow Cytometry MRD Test

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

Brian G.M. Durie, MD, Robert J. Kreitman, MD

Latest:

ASH Interview Series

The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.

Brian Hemphill, MD

Latest:

Dr. Hemphill on Molecular Profiling for Gastric Cancer Treatment

Brian Hemphill, MD, clinical oncologist, Tennessee Oncology, discusses molecular profiling for gastric cancer treatment.

Brian I. Rini, MD

Latest:

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

Brian I. Rini, MD, Cleveland Clinic

Latest:

Renal Cell Carcinoma: Future Evolutions in Care

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Brian J. Miles, MD

Latest:

Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer

Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.

Brian Larson, BS Pharm, RPh

Latest:

Is Your Practice Ready for New Rules on Hazardous Drug Management

Among community oncology practices, the US Pharmacopeia Convention’s General Chapter draft guidelines have already raised the bar for hazardous drug management and imposed costs for compliance.

Brian Leyland-Jones, MBBS, PhD

Latest:

Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Brian M. Shuch, MD

Latest:

Impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X)

Brian M. Shuch, MD, discusses the impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X).

Brian M. Slomivitz, MD

Latest:

Dr. Slomovitz on the Role of Surgery in Endometrial Cancer

Brian M. Slomovitz, MD, discusses the role of surgery in women with endometrial cancer.

Brian M. Slomovitz, MD

Latest:

Dr Slomovitz on the Importance of Education on Disease Management and Prevention During Gynecologic Cancer Awareness Month

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Brian M. Slomovitz, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System

Brian M. Wolpin, MD, MPH

Latest:

Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable safety profile, and encouraging survival outcomes in patients with RAS mutant pancreatic ductal adenocarcinoma.